Published online before print October 20, 2005, doi: 10.1161/01.ATV.0000191663.12164.77
© 2006 American Heart Association, Inc.
Brief Reviews |
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
From the Division of Endocrinology, Diabetes, and Hypertension (F.B., Y.T., E.C., W.A.H.), David Geffen School of Medicine, University of California, Los Angeles, Calif; the Department of Medicine/Cardiology (F.B.), German Heart Institute, Berlin, Germany; and the Department of Medical and Scientific Affairs (R.E.L.), Takeda Pharmaceuticals North America, Inc, Lincolnshire, Ill.
Correspondence to Florian Blaschke, Division of Endocrinology, Diabetes, and Hypertension, University of California, 900 Veteran Ave, Los Angeles, CA 90095. E-mail fblaschke{at}mednet.ucla.edu
Series Editor: Richard A. Cohen
ATVB In Focus Diabetic Vascular Disease: Pathophysiological Mechanisms in the Diabetic Milieu and Therapeutic Implications
Previous Brief Reviews in this Series:
•Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM. RAGE axis: animal models and novel insights into the vascular complications of diabetes. 2004;24:1342–1349.
•Natarajan R. Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. 2004;24:1542–1548.
•Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. 2005;25:487–496.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. The 3 PPAR isotypes, PPAR-
, PPAR-
, and PPAR-
, play a key role in the regulation of lipid and glucose metabolism. Obesity and the interrelated disorders of the metabolic syndrome have become a major worldwide health problem. In this review, we summarize the critical role of PPARs in regulating inflammation, lipoprotein metabolism, and glucose homeostasis and their potential implications for the treatment of obesity, diabetes, and atherosclerosis.
Obesity and the interrelated disorders of the metabolic syndrome have become a major worldwide health problem. In this review, we summarize the critical role of PPARs in regulating inflammation, lipoprotein metabolism, and glucose homeostasis and their potential implications for the treatment of obesity, diabetes, and atherosclerosis.
Key Words: PPARs • atherosclerosis • obesity • diabetes
This article has been cited by other articles:
 |
|
 |
|
  A. Taube, K. Eckardt, and J. Eckel Role of lipid-derived mediators in skeletal muscle insulin resistance Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1004 - E1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nadaf, F. Pitel, H. Gilbert, M. J. Duclos, F. Vignoles, C. Beaumont, A. Vignal, T. E. Porter, L. A. Cogburn, S. E. Aggrey, et al. QTL for several metabolic traits map to loci controlling growth and body composition in an F2 intercross between high- and low-growth chicken lines Physiol Genomics, August 7, 2009; 38(3): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Caglayan, B. Stauber, A. R. Collins, C. J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L. E. Peterson, R. S. Ross, et al. Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor {gamma} in Cardiac Fibrosis Diabetes, September 1, 2008; 57(9): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Desjardins, B. Sekkali, W. Verreth, M. Pelat, D. De Keyzer, A. Mertens, G. Smith, M.-C. Herregods, P. Holvoet, and J.-L. Balligand Rosuvastatin increases vascular endothelial PPAR{gamma} expression and corrects blood pressure variability in obese dyslipidaemic mice Eur. Heart J., January 1, 2008; 29(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Xu, S. R. Farmer, and B. D. Smith Peroxisome Proliferator-activated Receptor {gamma} Interacts with CIITA{middle dot}RFX5 Complex to Repress Type I Collagen Gene Expression J. Biol. Chem., September 7, 2007; 282(36): 26046 - 26056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice Diabetes, August 1, 2007; 56(8): 2036 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hiuge, A. Tenenbaum, N. Maeda, M. Benderly, M. Kumada, E. Z. Fisman, D. Tanne, Z. Matas, T. Hibuse, K. Fujita, et al. Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Giugliano and K. Esposito Optimal Treatments for the Metabolic Syndrome Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): e30 - e30. [Full Text] [PDF]
|
|